WHAT COMPANIES SAY – SURVEY RESULTS

For the 11th year in a row, PatientView invited pharma companies to input their own company perspectives on their patient-group relations into the 2026 series of reports on ‘The Corporate Reputation of Pharma—from the Patient Perspective’.

This year’s theme for pharma-company patient-related achievements is one that emerged from previous ‘Corporate Reputation’ results as being of increasing interest to patient groups: “How EFFECTIVELY does your company currently address five R&D DEMANDS from patient groups?”

Companies’ stories about their latest achievements in engaging patients in R&D, and published in April 2026 by PatientView in this stand-alone document, ‘What Companies Say, 2025-2026’, has been placed into the public domain—available to anyone. Additionally, all respondent companies (and all patient groups responding to the 2025-2026 ‘Corporate Reputation’ survey) have been sent a copy of these corporate contributions.

The companies participating in ‘What Companies Say, 2025-2026’:

→ Boehringer Ingelheim

→ Novartis

→ Servier

→ ViiV Healthcare

---

WHAT COMPANIES SAY 2025-2026 – RESULTS AVAILABLE HERE

---

If you have any questions PLEASE DO NOT HESITATE TO CONTACT ALEX WYKE ON [email protected]